Additional file 1: Figure S1. of Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain
M. Sanchez-Luna
R. Burgos-Pol
I. Oyagüez
J. Figueras-Aloy
M. Sánchez-Solís
F. Martinón-Torres
X. Carbonell-Estrany
10.6084/m9.figshare.c.3907168_D1.v1
https://springernature.figshare.com/articles/journal_contribution/Additional_file_1_Figure_S1_of_Cost-utility_analysis_of_Palivizumab_for_Respiratory_Syncytial_Virus_infection_prophylaxis_in_preterm_infants_update_based_on_the_clinical_evidence_in_Spain/5509060
Curve fitting to get the palivizumab effect on recurrent wheezing over 61 years by using RR values from the literature. (DOCX 19 kb)
2017-10-17 05:00:00
Cost-effectiveness
Preterm infants
Palivizumab
RSV infection
Recurrent wheezing